Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.71 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.71 |
| ▸ | MGLL | Q99685 | 1/20 | 0.71 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.71 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897766 | 0.90 | FAAH (0.70) | FAAHMAPTBLMPPARGPPARD | |
| SCHEMBL2897767 | 0.90 | FAAH (0.70) | FAAHMAPTBLMPPARGPPARD | |
| Arachidonyl Trifluoromethylketone SCHEMBL30426991 | 0.83 | FAAH (1.00) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| Arachidonyl Trifluoromethylketone SCHEMBL9880640 | 0.83 | FAAH (1.00) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL30211917 | 0.81 | CNR1 (0.76) | ALDH1A1MAPTBLMPPARGPPARD | |
| SCHEMBL12988176 | 0.81 | FABP3 (0.77) | FAAHALDH1A1MAPTBLMPPARG | |
| SCHEMBL459981 | 0.80 | FAAH (0.93) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL459980 | 0.80 | FAAH (0.93) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL20971537 | 0.80 | PPARG (0.73) | ALDH1A1MAPTBLMPPARGPPARD | |
| Arachidonic Acid SCHEMBL28580781 | 0.79 | PPARG (0.78) | FAAHPLA2G4AALDH1A1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114767859-A | Application of targeting cPLA2 in prevention and treatment of radiation-induced lung injury | 山东大学齐鲁医院 | 2022-07-22 | — | — | CN | claimed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-9328060-B2 | J-series prostaglandin-ethanolamides as novel therapeutics | EAST CAROLINA UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| EP-2949344-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150111969-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS | EAST CAROLINA UNIVERSITY | 2015-04-23 | — | — | US | disclosed |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2685969-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012129112-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2010151160-A1 | O-SUBSTITUTED 3-N-HETEROARYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL - PORTELA & CA., S.A. (PT) | 2010-12-29 | — | — | WO | disclosed |
| EP-2238131-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL - Portela & Ca., S.A. (PT) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010074587-A2 | 5-O-SUBSTITUTED 3-N-ARYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL - PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
| WO-2009084970-A1 | 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE | BIAL-PORTELA & COMPANHIA, S.A. (PT) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111969-A1 | J-SERIES PROSTAGLANDIN-ETHANOLAMIDES AS NOVEL THERAPEUTICS | PTGER2, FAAH2, PTGER1 | FAAH 6/4885PLA2G4A 33/4885ALDH1A1 485/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | FAAH 842/4885PLA2G4A 72/4885ALDH1A1 1198/4885 |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | GAA, GUSB, ACER2 | FAAH 766/4885PLA2G4A 92/4885ALDH1A1 1139/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | FAAH 3780/4885PLA2G4A 3121/4885ALDH1A1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.